Aclaris Therapeutics Says Phase 1 Trial of Dermatitis Therapy Candidate ATI-052 Shows 'Strong Safety' Profile

MT Newswires Live

01/06

Aclaris Therapeutics (ACRS) said Tuesday its atopic dermatitis and asthma therapy candidate ATI-052 showed a 'strong safety and tolerability profile' in interim phase 1 trial results.

The interim data also showed the candidate had a 'dose proportional pharmokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose.'

Aclaris plans to initiate phase 1b trials for atopic dermatitis 'imminently' and asthma therapy in Q1, with top line data from both trials to be released in H2.

The company is also planning a phase 2b trial of ATI-052 in atopic dermatitis to begin in H2.

Shares of the company were up 3.4% in recent Tuesday premarket activity.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2601937897"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601937897\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601937897?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601937897","market":"sh","top_or_hot":-1,"title":"Aclaris Therapeutics Says Phase 1 Trial of Dermatitis Therapy Candidate ATI-052 Shows 'Strong Safety' Profile","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ACRS\">Aclaris Therapeutics</a> (ACRS) said Tuesday its atopic dermatitis and asthma therapy candidate ATI-052 showed a 'strong safety and tolerability profile' in interim phase 1 trial results.</p><p>The interim data also showed the candidate had a 'dose proportional pharmokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose.'</p><p>Aclaris plans to initiate phase 1b trials for atopic dermatitis 'imminently' and asthma therapy in Q1, with top line data from both trials to be released in H2.</p><p>The company is also planning a phase 2b trial of ATI-052 in atopic dermatitis to begin in H2.</p><p>Shares of the company were up 3.4% in recent Tuesday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aclaris Therapeutics Says Phase 1 Trial of Dermatitis Therapy Candidate ATI-052 Shows 'Strong Safety' Profile</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAclaris Therapeutics Says Phase 1 Trial of Dermatitis Therapy Candidate ATI-052 Shows 'Strong Safety' Profile\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-01-06 21:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ACRS\">Aclaris Therapeutics</a> (ACRS) said Tuesday its atopic dermatitis and asthma therapy candidate ATI-052 showed a 'strong safety and tolerability profile' in interim phase 1 trial results.</p><p>The interim data also showed the candidate had a 'dose proportional pharmokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose.'</p><p>Aclaris plans to initiate phase 1b trials for atopic dermatitis 'imminently' and asthma therapy in Q1, with top line data from both trials to be released in H2.</p><p>The company is also planning a phase 2b trial of ATI-052 in atopic dermatitis to begin in H2.</p><p>Shares of the company were up 3.4% in recent Tuesday premarket activity.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B7SZL793.SGD","symbol_name":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2601937897","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601937897","pubTimestamp":1767704534,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Aclaris Therapeutics  said Tuesday its atopic dermatitis and asthma therapy candidate ATI-052 showed a 'strong safety and tolerability profile' in interim phase 1 trial results.The interim data also showed the candidate had a 'dose proportional pharmokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose.'Aclaris plans to initiate phase 1b trials for atopic dermatitis 'imminently' and asthma therapy in Q1, with top line data from both trials to be released in H2.The company is also planning a phase 2b trial of ATI-052 in atopic dermatitis to begin in H2.Shares of the company were up 3.4% in recent Tuesday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","ACRS":"Aclaris Therapeutics","ATI":"阿利根尼","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","BK4187":"航天航空与国防","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","BK4007":"制药","BK4006":"钢铁"},"translate_title":"Aclaris Therapeutics表示皮炎候选疗法ATI-052的1期试验显示出“强大的安全性”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACRS":1.5,"ATI":1.5},"content_text":"Aclaris Therapeutics (ACRS) said Tuesday its atopic dermatitis and asthma therapy candidate ATI-052 showed a 'strong safety and tolerability profile' in interim phase 1 trial results.The interim data also showed the candidate had a 'dose proportional pharmokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose.'Aclaris plans to initiate phase 1b trials for atopic dermatitis 'imminently' and asthma therapy in Q1, with top line data from both trials to be released in H2.The company is also planning a phase 2b trial of ATI-052 in atopic dermatitis to begin in H2.Shares of the company were up 3.4% in recent Tuesday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}